74 results about "Telangiectasia" patented technology

A system and method for treating subcutaneous histological features without affecting adjacent tissues adversely employs microwave energy of selected power, frequency and duration to penetrate subcutaneous tissue and heat target areas with optimum doses to permanently affect the undesirable features. The frequency chosen preferentially interacts with the target as opposed to adjacent tissue, and the microwave energy is delivered as a short pulse causing minimal discomfort and side effects. By distributing microwave energy at the skin over an area and adjusting power and frequency, different conditions, such as hirsuitism and telangiectasia, can be effectively treated.

The present invention features novel cosmetic skin care compositions for improving the appearance of rosacea-affected skin.

Embodiments relating to gels comprising imidazoline alpha agonists, such as, without limitation, oxymetazoline or a pharmaceutically acceptable salt thereof, and methods for treating diseases, such as, without limitation, rosacea, including, for example, erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, ocular rosacea or combinations thereof; and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema or redness associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith or combinations thereof using such gels are described herein.

This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof. Other embodiments consist of the combination of an amphiphilic block copolymer with a co-solvent, also allowing the injected combination to form a gel within the vein. In other embodiments, an amphiphilic block copolymer is combined with a co-solvent, a sclerosant, a vasoconstrictor, water, or combinations thereof. Other embodiments of the invention include a combination of a sclerosant such as sodium tetradecyl sulfate or polidocanol with a vasoconstrictor, preferably a long-acting vasoconstrictor such as oxymetazoline. Other embodiments are directed to compositions and methods of treating venous and arteriovenous malformations and cancer.

The invention provides a traditional Chinese medicine composition for treating rosacea. The composition is prepared from the following medicines in portion by weight: 10 to 20 portions of fresh liquorice, 25 to 35 portions of china roots, 25 to 35 portions of paniculate swallowwort roots, 5 to 15 portions of Chinese red pepper, 15 to 25 portions of radix cyathulae, 15 to 25 portions of atractylodes, 5 to 15 portions of mint, 15 to 25 portions of phellodendron, 15 to 25 portions of Baikal skullcap roots, 15 to 25 portions of sophora flavescens, 25 to 35 portions of belvedere fruit, 5 to 15 portions of radix stemonae and 10 to 20 portions of common cnidium fruit. The composition has the efficacies of n clearing heat and toxic materials, killing worms, relieving itching and the like. When the composition is used, a method of smearing the composition on erythema as well as papule and pustule on telangiectasia is adopted. The composition is convenient to use, is applied five times a day, takes four weeks as a treatment course, can cure the patients with mild symptoms after 3 to 4 treatment courses, can obviously improve the state of the patients with severe symptoms, and is short in treatment time.

The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.

The invention discloses a bone healing treatment instrument, which comprises a power generating device and an output electrode. The power producing device transmits series of sine wave electrical signals to the output electrode, which then produces an electric filed (frequency ranging from 80Hz to 120Hz) to take effect on the bone nonunion parts. The invention also discloses a bone healing treatment. The instrument can stimulate the bone nonunion parts with the low frequency (80Hz to 120Hz) signals, and accelerate the bone callus growing. The invention can significantly improve the partial skin pain threshold, and distend the partial telangiectasia. At the same time, the invention has good stimulation effect on the motor nerve and the muscle tissue, and accelerates the bone nonunion healing in various ways with little skin irritation.

The invention relates to a umbilical therapy device, which includes an umbilical therapy box, an electric heater and a medicinal magnetic bag lining pad, the umbilical therapy box is used for containing the electric heater and the medicinal magnetic bag lining pad, a medicinal magnetic bag is arranged on the medicinal magnetic bag lining pad, medicine is arranged in the medicinal magnetic bag, the ingredients of the medicine include pricklyash peel, haiercha, fennel fruit, pepper, hedgehog hide, Chinese magnoliavine fruit, dahurian angelica root, round cardamom fruit and magnetite, the medicine is transdermally absorbed and combined with the magnetic therapy and the thermal therapy, the medicine is directly acted on the intestine by passing through the umbilical point, all the ingredients can achieve the effects of warming spleen and stomach, relieving diarrhea with astringents, resolving food, removing expansion and relieving pain; the hot compression performs the effects of warming spleen and stomach, activating collaterals, dispelling cold, stopping pain and promoting telangiectasia; and the magnetic therapy performs the effects of dredging meridians and anti-inflammation. The combination of the three therapies increases the umbilical penetration force of the medicine, the functions of the medicine, the magnet and the heat are overlapped, thereby being applicable to the treatment of non-infectious diarrhea and indigestion of children; compared with the single therapy, the efficacy is improved, the transdermal absorption of the medicine is greatly improved and the treatment effects are improved.

The present invention relates to a dermocosmetic composition of localised topical application in cream and/or emulsion form, to the procedure for obtainment thereof together with use thereof for care and correction of telangiectasias and to the method of administration thereof.

A compound represented by the formula (1):

or a pharmaceutically acceptable salt thereof can reduce a score of telangiectasia around the meibomian gland orifices and a number of obstruction at the orifices, so that it is useful as a prophylactic and/or therapeutic agent for meibomian gland dysfunction.

A system and method for treating vessel in skin is disclosed. The system may include two or more electrodes that may be inserted in skin to deliver electrical signal to target vessel therein, an electrical signal generator electrically coupled to the plurality of electrodes, and a power supply unit for supplying power to the electrical signal generator. The system and method may be employed to selectively reduce hypervascularity in the dermis or epidermis by generating thermal damage thereto or inducing phagocytosis or apoptosis of vascular cell in order to treat melasma, dermal melasma, hyperpigmentation, hypopigmentation, rosacea, flushing, erythema, or telangiectasia, while lowering the risk of excessive heating of the skin vessel encountered in and reducing the rate of re-occurrence of rebounded vascularization associated with conventional LASER treatments for melasma, dermal melasma, hyperpigmentation, hypopigmentation, rosacea, flushing, erythema, or telangiectasia.

The invention discloses a moisture retention and skin moisturizing liquid containing pittosporum tobira ait essential oil and a honeysuckle extract, wherein the moisture retention and skin moisturizing liquid comprises, by mass, 0.2% of pittosporum tobira ait essential oil with a concentration of 1 wt%, 2% of propylene glycol, 2% of glycerol, 0.1% of hyaluronic acid, 0.5% of sodium hydroxymethylglycinate, 1.5% of a honeysuckle extract with a concentration of 0.1 wt%, 0.25% of lactic acid, and 93.45% of water. According to the present invention, by adding the pittosporum tobira ait essential oil and the honeysuckle extract, the effects of skin fine line eliminating, aging preventing, telangiectasia improving, and relieving of red swelling of the skin can be provided, and the obtained moisture retention and skin moisturizing liquid can be used for improving and preventing skin aging and repairing the sun-exposed skin and the allergic skin; and the moisture retention and skin moisturizing liquid does not contain heavy metals, alcohols, hormones, mineral oil, pigment and other ingredients, has the soft formula, and cannot cause irritation and burden on the skin.

The invention discloses external rubbing spreading medicinal liquor for tinea capitis (tinea alba) and a preparation method thereof. The external rubbing spreading medicinal liquor is prepared from the following main raw materials in parts by weight: 20 parts of loofah sponge, 10 parts of radix saposhnikoviae, 17 parts of fructus gardeniae, 9 parts of platycodon grandiflorum, 10 parts of chinese prickly ash, 65 parts of fresh celosia cristata, 1.8 parts of camphor, 2.1 parts of borneol and 500 parts of brandy. The product disclosed by the invention can effectively improve the microcirculation state of head skin and promote the telangiectasia, promote the blood circulation, activate the activity of hair mother cells and enhance the exchange and penetration capacity of multiple fibers and hair follicles of the head skin by referring to the modern pharmacological research on the basis of summarizing the experiences of predecessors, thereby achieving the purpose of treating the tinea capitis (tinea alba) by enabling the hair follicles to recover functions again and absorb needed nutrients.

There are provided methods and compositions for improving the aesthetic appearance of akin, treating rosacea and/or telangiectasia, and treating the signs of dermatological aging. The method is directed to topically applying to an affected area an effective amount of mangostin, an analog thereof, or a combination thereof.

The invention discloses application of an HOIP inhibitor in preparation of a medicine for treating type II hereditary hemorrhagic telangiectasia (HHT2). Firstly, a binding domain and a binding mechanism of ALK1 kinase and HOIP are disclosed, and it is found that binding enhancement of an ALK1 mutant and HOIP promotes obvious enhancement of the ubiquitination levels. By inhibiting the activity of HOIP ubiquitin ligase, the ubiquitination level of the ALK1 mutant is reduced, so that an ALK1-Smad1/5 signaling pathway is recovered, and symptoms of HHT2 are relieved. The invention proves that the pathogenesis of the ALK1 mutation-induced HHT2 is the reduction of the enzyme activity of ALK1 kinase, and a specific mutant of ALK1 can be inhibited through the HOIP inhibitor, so that the HOIP inhibitor can be used for treating HHT2, and the HOIP inhibitor becomes a potential medicine for treating the specific ALK1 mutation-induced HHT2.

Improved methods and compositions for safe and effective treatment of telangiectasia or a symptom associated with telangiectasia in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.